Retinoic acid syndrome

Retinoic acid syndrome
Other namesDifferentiation syndrome
SpecialtyOncology, hematology

Retinoic acid syndrome (RAS) is a potentially life-threatening complication observed in people with acute promyelocytic leukemia (APML) and first thought to be specifically associated with all-trans retinoic acid (ATRA) (also known as tretinoin) treatment.[1] Subsequently, so-called RAS was recognized in APML patients who had been treated with another highly efficacious drug, arsenic trioxide, and yet did not appear in patients treated with tretinoin for other disorders. These facts and others support the notion that RAS depends on the presence of the malignant promyelocytes. This has led to the growing deprecation of the term 'retinoic acid syndrome' and to an increasing use of the term differentiation syndrome to signify this APML treatment complication.[2]

  1. ^ Breccia M, Latagliata R, Carmosino I, Cannella L, Diverio D, Guarini A, et al. (December 2008). "Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin". Haematologica. 93 (12): 1918–1920. doi:10.3324/haematol.13510. PMID 18945746.
  2. ^ Weinberger S, Larson RA. "Differentiation (retinoic acid) syndrome". Up To Date. Waltham MA. Retrieved 10 March 2011.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.